Experimental approaches to TSE prevention via inhibition of prion formation.
Transmissible spongiform encepahalopathies (TSEs) are fatal diseases that damage the central nervous system. TSEs are unique in that they may be inherited, infectious or spontaneous. The central pathogenic agent is thought to be a conformationally distinct form (PrP(Sc;)) of the endogenous prion protein(PrP(c)), which is high in beta-sheet content and is resistant to proteases; infectivity is thought to involve formation of PrP(Sc) via imprinting of abnormal conformation on the normal form of the protein (PrP(c)) by seeds of PrP(Sc). A number of compounds found to inhibit the conversion of PrP(c) to PrP(Sc) have been proposed as therapeutics to halt TSEs.
Politopoulou
Galatia
G
Department of Rheumatology, Avon Orthopaedic Centre, Southmead Hospital, University of Bristol. g.politopoulou@bristol.ac.uk
D000818:Animals; D006801:Humans; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D017096:Prion Diseases / Q000378:metabolism* / Q000517:prevention & control* / Q000628:therapy; D011328:Prions / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism* / Q000472:pathogenicity
D010455:Peptides; D011328:Prions